Dr. Reddy's Prilosec OTC generic arrives
This article was originally published in The Tan Sheet
Executive Summary
The first major competition for Perrigo's private-label proton pump inhibitor hits shelves after a delay, Dr. Reddy's says. Perrigo has said it does not expect the India-based generics firm's capsule version of Procter & Gamble's Prilosec OTC to substantially affect sales of its own omeprazole tablet (1"The Tan Sheet" Nov. 9, 2009). In a Dec. 15 note, Collins Stewart analyst Louise Chen points out Perrigo has an 18-month head start on Dr. Reddy's, which she expects will only "take modest market share away" from Perrigo. A same-day Goldman Sachs report says Perrigo expects to maintain annual omeprazole sales of over $200 million, assuming an 80-percent to 90-percent share of the generic Prilosec OTC market, which itself is approaching 50 percent of all OTC omeprazole
You may also be interested in...
AstraZeneca's Prilosec OTC suit deemed "frivolous"
AstraZeneca must pay Dr. Reddy's attorneys' fees for a patent infringement case, says Judge Colleen McMahon of the U.S. District Court for the Southern District of New York. She writes in a March 30 1decision that AstraZeneca lacked evidence that Dr. Reddy's abbreviated new drug application for a Prilosec OTC equivalent infringed its patents. "I certainly hope that this ruling chills the sort of unreasonable, frivolous, anti-competitive, anti-consumer litigation in which plaintiffs here engaged," McMahon writes. Dr. Reddy's won the suit in March 2009, but did not launch its generic omeprazole capsule until late 2009 (2"The Tan Sheet" Dec. 21, 2009, In Brief)
Perrigo Strives To Stand Out Against Incoming Private Label Competition
Even as Perrigo products face the prospect of increasingly crowded segments, the company likes where it stands among private label competition
Lilly Looks To Accelerate Tirzepatide Into Obesity With Rolling Submission
Plan for rolling submission means US FDA filing of GIP/GLP1 agonist in obesity could be complete by April 2023, setting up possibility of late 2023 approval.